Programmed Death Ligand-1-directed Antibody Interactions

Programmed Death Ligand-1 Antagonists

Programmed Death Ligand-1 Blocker

Carcinoma, Transitional Cell

<section class="Section" data-sectioncode="34089-3"><a name="ID_665a20ed-c837-4683-a1d1-ca96615a2f86"></a><a name="section-8"></a><p></p><h1>11 DESCRIPTION </h1><p class="First">Durvalumab is a programmed cell death ligand 1 (PD-L1) blocking antibody. Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that is produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture.</p><p>IMFINZI (durvalumab) Injection for intravenous use is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution, free from visible particles.</p><p>Each 500 mg vial of IMFINZI contains 500 mg of durvalumab in 10 mL solution. Each mL contains durvalumab, 50 mg, L-histidine (2 mg), L-histidine hydrochloride monohydrate (2.7 mg), α,α-trehalose dihydrate (104 mg), Polysorbate 80 (0.2 mg), and Water for Injection, USP.</p><p>Each 120 mg vial of IMFINZI contains 120 mg of durvalumab in 2.4 mL solution. Each mL contains durvalumab, 50 mg, L-histidine (2 mg), L-histidine hydrochloride monohydrate (2.7 mg), α,α-trehalose dihydrate (104 mg), Polysorbate 80 (0.2 mg), and Water for Injection, USP.</p></section>

IMFINZI

durvalumab

2.4 ML durvalumab 50 MG/ML Injection

Imfinzi

2.4 ML durvalumab 50 MG/ML Injection [Imfinzi]

10 ML durvalumab 50 MG/ML Injection

10 ML durvalumab 50 MG/ML Injection [Imfinzi]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Reimbursement Information

Pharmacy List

How to Order Imfinzi

Billing & Coding Guide

Coverage Authorization Request 

Coverage Authorization Appeals 

Imfinzi Enrollment Form

Enroll in Patient Savings Program - HCP Portal

Enroll in Patient Savings Program - Patient 

AZ & Me Prescription Savings Program - Patient Assistance Program 

AstraZeneca 360 Access - HCP Portal 

Imfinzi Affordability Brochure

Imfinzi Affordability Brochure - Spanish

Other HCP Resources: Advanced or Metastatic Biliary Tract Cancer (BTC)

Instructions For Use: Advanced or Metastatic Biliary Tract Cancer (BTC)

Patient Reported Outcomes: Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Other HCP Resources: Extensive-stage Small Cell Lung Cancer (ES-SCLC)

About Imfinzi: Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Taking Imfinzi: Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Doctor Discussion Guide: Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Patient Resources: Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Caregiver Resources: Extensive-stage Small Cell Lung Cancer (ES-SCLC)

 FAQs: Extensive-stage Small Cell Lung Cancer (ES-SCLC)

 Instructions For Use: Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Imfinzi Support Sign Up

Other HCP Resources: Stage III Non-small Cell Lung Cancer (NSCLC)

About Imfinzi: Stage III Non-small Cell Lung Cancer (NSCLC)

Taking Imfinzi: Stage III Non-small Cell Lung Cancer (NSCLC)

Side Effects: Stage III Non-small Cell Lung Cancer (NSCLC)

Caregiver Resources: Stage III Non-small Cell Lung Cancer (NSCLC)

FAQs: Stage III Non-small Cell Lung Cancer (NSCLC)

Patient Resources: Stage III Non-small Cell Lung Cancer (NSCLC)

Patient Resources- Advocacy & Community: Stage III Non-small Cell Lung Cancer (NSCLC)